Red Arrow Therapeutics Inc.
- Biotech or pharma, therapeutic R&D
Red Arrow Therapeutics is a Delaware C-corp spun out of the University of Tokyo developing biocompatible nanopolymer based drug delivery systems which safely and precisely deliver life-saving biologics. Our proprietary pH-sensitive nanopolymers self-assemble into micelles that shield fragile and or systemically toxic payloads, and only open at the target disease site like a Trojan horse. Our lead pipeline interleukin-12 systemically to eradicate solid tumors while sparing healthy tissue and is tracking toward IND filing in early 2027. Future pipelines are planned to include ADCs, T-cell engagers, and gene editing technology. Founded in 2021, we have raised $8.5 M in seed funding and have been selected to receive up to $47M in non-dilutive funding by the Japanese government. We are raising our $30M seed round 2025Q4-2026Q1.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}